| Selected Quarterly Data (Unaudited) |
|
18.
|
Selected Quarterly Data (Unaudited)
|
| |
|
2011
|
|
| |
|
For the Quarter Ended
|
|
| |
|
March 31
|
|
|
June 30
|
|
|
September 30
|
|
|
December 31
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
Expenses
|
|
|
(3,913,340 |
) |
|
|
(6,458,586 |
) |
|
|
(3,355,059 |
) |
|
|
(2,404,028 |
) |
|
Loss from Operations
|
|
|
(3,913,340 |
) |
|
|
(6,458,586 |
) |
|
|
(3,355,059 |
) |
|
|
(2,404,028 |
) |
|
Other Income (Expense)
|
|
|
(522,821 |
) |
|
|
629,734 |
|
|
|
1,885,841 |
|
|
|
2,793,309 |
|
|
Net Loss (Income)
|
|
$ |
(4,436,161 |
) |
|
$ |
(5,828,852 |
) |
|
$ |
(1,469,218 |
) |
|
$ |
389,281 |
|
|
Net Loss (Income) per share, basic and diluted
|
|
$ |
(0.05 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.02 |
) |
|
$ |
0.00 |
|
| |
|
2010
|
|
| |
|
For the Quarter Ended
|
|
| |
|
March 31
|
|
|
June 30
|
|
|
September 30
|
|
|
December 31
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
Expenses
|
|
|
(1,593,118 |
) |
|
|
(3,189,014 |
) |
|
|
(2,367,526 |
) |
|
|
(3,156,251 |
) |
|
Loss from Operations
|
|
|
(1,593,118 |
) |
|
|
(3,189,014 |
) |
|
|
(2,367,526 |
) |
|
|
(3,156,251 |
) |
|
Other Income (Expense)
|
|
|
(6,440,478 |
) |
|
|
(408,056 |
) |
|
|
2,586,417 |
|
|
|
545,919 |
|
|
Net Loss (Income)
|
|
$ |
(8,033,596 |
) |
|
$ |
(3,597,070 |
) |
|
$ |
218,891 |
|
|
$ |
(2,610,332 |
) |
|
Net Loss (Income) per share, basic and diluted
|
|
$ |
(0.11 |
) |
|
$ |
(0.05 |
) |
|
$ |
0.00 |
|
|
$ |
(0.03 |
) |
For the quarters ended June 30, 2011 and previous, the Company had reported $18,750 in revenue from the amortization of the Rexgene contribution as described in Note 9. The Company reclassified the revenue to a reduction of research and development expenses in the Statement of Operations. The reclassification had no effect on the Company's net loss or net loss per share for all quarters presented.
|